BR112016016103A2 - Composição de antígenos micobacterianos - Google Patents
Composição de antígenos micobacterianosInfo
- Publication number
- BR112016016103A2 BR112016016103A2 BR112016016103A BR112016016103A BR112016016103A2 BR 112016016103 A2 BR112016016103 A2 BR 112016016103A2 BR 112016016103 A BR112016016103 A BR 112016016103A BR 112016016103 A BR112016016103 A BR 112016016103A BR 112016016103 A2 BR112016016103 A2 BR 112016016103A2
- Authority
- BR
- Brazil
- Prior art keywords
- mycobacterial
- composition
- sequence
- polynucleotide
- antigenic polypeptide
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 5
- 108091033319 polynucleotide Proteins 0.000 abstract 5
- 239000002157 polynucleotide Substances 0.000 abstract 5
- 230000000890 antigenic effect Effects 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Mycobacteriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/5695—Mycobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6006—Cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
COMPOSIÇÃO DE ANTÍGENOS MICOBACTERIANOS. A presente invenção provê uma composição antigênica para uso como vacina contra micobactérias, em que a referida composição compreende (i) um primeiro polipeptídeo antigênico micobacteriano, em que o referido primeiro polipeptídeo antigênico micobacteriano compreende a sequência polipeptídica tendo ao menos 70% de identidade de sequência de aminoácidos com a sequência de aminoácidos de SEQ ID NO: 6, 12, 2, 18, 8, 10, 16, 4, ou seu fragmento tendo ao menos 50 aminoácidos consecutivos dessa sequência; ou (ii) um primeiro polinucleotídeo micobacteriano, em que o referido primeiro polinucleotídeo micobacteriano compreende uma sequência polinucleotídica codificadora do referido primeiro polipeptídeo antigênico micobacteriano, ou em que o referido primeiro polinucleotídeo micobacteriano compreende uma sequência polinucleotídica selecionada a partir de SEQ ID NO: 5, 11, 1, 17, 7, 9, 15 ou 3.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1400819.7A GB201400819D0 (en) | 2014-01-17 | 2014-01-17 | Mycobacterial antigen composition |
| PCT/GB2015/050100 WO2015107363A2 (en) | 2014-01-17 | 2015-01-16 | Mycobacterial antigen composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016016103A2 true BR112016016103A2 (pt) | 2017-09-19 |
Family
ID=50239107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016016103A BR112016016103A2 (pt) | 2014-01-17 | 2015-01-16 | Composição de antígenos micobacterianos |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20160326236A1 (pt) |
| EP (2) | EP3281638B1 (pt) |
| CN (1) | CN106102768B (pt) |
| AU (1) | AU2015207374B2 (pt) |
| BR (1) | BR112016016103A2 (pt) |
| CA (1) | CA2936051A1 (pt) |
| GB (1) | GB201400819D0 (pt) |
| RU (1) | RU2702194C2 (pt) |
| WO (1) | WO2015107363A2 (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2651437B1 (en) * | 2010-12-14 | 2016-02-10 | GlaxoSmithKline Biologicals S.A. | Mycobacterium antigenic composition |
| SG11201500171YA (en) * | 2012-07-10 | 2015-02-27 | Transgene Sa | Mycobacterial antigen vaccine |
| WO2019144139A1 (en) * | 2018-01-22 | 2019-07-25 | Oregon State University | Immunogenic compositions comprising mycobacterium bovis surface proteins and uses thereof |
| CN111471632B (zh) * | 2020-02-28 | 2022-03-08 | 中国科学院广州生物医药与健康研究院 | 一种重组耐药bcg菌株的构建方法及其应用 |
| CN112899295A (zh) * | 2021-03-22 | 2021-06-04 | 中国人民解放军空军军医大学 | 表达结核分枝杆菌多阶段抗原融合蛋白的重组腺病毒及其用途 |
| CN113985026B (zh) * | 2021-09-29 | 2023-12-26 | 重庆市畜牧科学院 | 一种检测羊副结核分枝杆菌的elisa试剂盒及其应用 |
| CN115920003A (zh) * | 2022-08-31 | 2023-04-07 | 中国医学科学院病原生物学研究所 | 脂蛋白LprG及其基因作为抗结核分枝杆菌药物靶点的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6294328B1 (en) * | 1998-06-24 | 2001-09-25 | The Institute For Genomic Research | DNA sequences for strain analysis in Mycobacterium tuberculosis |
| CA2375448C (en) * | 1999-06-09 | 2009-04-07 | Victoria Pope | Method for detecting syphilis using synthetic antigens |
| AU2002306849A1 (en) * | 2001-03-21 | 2002-10-08 | Elitra Pharmaceuticals, Inc. | Identification of essential genes in microorganisms |
| AU2002314358C1 (en) * | 2001-07-04 | 2009-03-26 | The Secretary Of State For Health | Mycobacterial antigens expressed during latency |
| US7074559B2 (en) * | 2002-03-06 | 2006-07-11 | Refents of the University of Minnesota | Mycobacterial diagnostics |
| GB0406271D0 (en) * | 2004-03-19 | 2004-04-21 | Isis Innovation | Diagnostic test |
| GB201008512D0 (en) * | 2010-05-21 | 2010-07-07 | Health Prot Agency | Mycobacterial antigen composition |
| SG11201500171YA (en) * | 2012-07-10 | 2015-02-27 | Transgene Sa | Mycobacterial antigen vaccine |
-
2014
- 2014-01-17 GB GBGB1400819.7A patent/GB201400819D0/en not_active Ceased
-
2015
- 2015-01-16 AU AU2015207374A patent/AU2015207374B2/en not_active Ceased
- 2015-01-16 EP EP17192244.6A patent/EP3281638B1/en active Active
- 2015-01-16 US US15/110,932 patent/US20160326236A1/en not_active Abandoned
- 2015-01-16 BR BR112016016103A patent/BR112016016103A2/pt not_active IP Right Cessation
- 2015-01-16 WO PCT/GB2015/050100 patent/WO2015107363A2/en active Application Filing
- 2015-01-16 CA CA2936051A patent/CA2936051A1/en not_active Abandoned
- 2015-01-16 CN CN201580009239.8A patent/CN106102768B/zh not_active Expired - Fee Related
- 2015-01-16 EP EP15701245.1A patent/EP3094349A2/en not_active Withdrawn
- 2015-01-16 RU RU2016133598A patent/RU2702194C2/ru active
-
2017
- 2017-08-08 US US15/672,085 patent/US11021534B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3281638A1 (en) | 2018-02-14 |
| AU2015207374A1 (en) | 2016-07-21 |
| RU2016133598A (ru) | 2018-02-22 |
| CN106102768A (zh) | 2016-11-09 |
| WO2015107363A2 (en) | 2015-07-23 |
| RU2702194C2 (ru) | 2019-10-04 |
| EP3094349A2 (en) | 2016-11-23 |
| US11021534B2 (en) | 2021-06-01 |
| EP3281638B1 (en) | 2020-05-20 |
| US20180066043A1 (en) | 2018-03-08 |
| WO2015107363A3 (en) | 2015-10-15 |
| AU2015207374B2 (en) | 2020-06-25 |
| US20160326236A1 (en) | 2016-11-10 |
| GB201400819D0 (en) | 2014-03-05 |
| CA2936051A1 (en) | 2015-07-23 |
| RU2016133598A3 (pt) | 2018-09-28 |
| CN106102768B (zh) | 2020-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016016103A2 (pt) | Composição de antígenos micobacterianos | |
| ES2721309T3 (es) | Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa | |
| BR112017008165A2 (pt) | anticorpos de domínio único direcionados contra antígenos intracelulares | |
| BR112016028066A2 (pt) | composição de vacina; idessuis; ridessuis; anticorpo; composição parenteral; uso de uma proteína idessuis ou ridessuis; e célula hospedeira | |
| BR112012018951A8 (pt) | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica | |
| BR112017023646A2 (pt) | proteínas agonistas de receptor de cd40 de cadeia simples | |
| ES2722773T3 (es) | Polipéptidos de fHbp meningocócicos modificados | |
| BR112018077188A2 (pt) | frutose-6-fosfato-3-epimerase termoestável inovadora e um método para produzir alulose com o uso da mesma | |
| CY1119916T1 (el) | Ανοσογονικη συνθεση | |
| BR112017019625A2 (pt) | udp-glicosiltransferases | |
| BR112012018947B8 (pt) | anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica | |
| BR112018011059A2 (pt) | synp161, um promotor para a expressão específica de genes em fotoreceptores de haste | |
| BR112018077358A2 (pt) | tagatose-6-fosfato fosfatase termoestável inovadora e um método para produzir tagatose com o uso da mesma | |
| BR112017020308A2 (pt) | udp-glicosiltransferases | |
| BR112017009790A2 (pt) | anticorpos direcionados ao anti-ang2 e métodos de uso | |
| BR112017011556A2 (pt) | métodos para gerar um anticorpo sintético, prevenir ou tratar uma doença, tratar um sujeito de infecção por um patógeno e um sujeito com câncer, produto, molécula de ácido nucleico, e, composição. | |
| BR112017018703A2 (pt) | peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno | |
| EA201790558A1 (ru) | Композиция с пониженной иммуногенностью | |
| BR112016026842A2 (pt) | preparação compreendendo fator viii e peptídeos de fator de von willebrand | |
| BR112014030440A8 (pt) | método para preparar um alqueno monoinsaturado | |
| BR112017013453A2 (pt) | novo peptídeo inibidor de pi3ky para o tratamento de doenças do sistema respiratório | |
| BR112017010832A2 (pt) | composições de aminoácido para o tratamento de sintomas de doença | |
| BR112018008840A8 (pt) | anticorpos de domínio único direcionados contra antígenos intracelulares | |
| BR112017014598A2 (pt) | métodos e usos para hidrólise de queratina | |
| BR112017006969A2 (pt) | peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígeno |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2705 DE 08-11-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |